Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
+$0.03 today
- Market cap
- $169.16M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
Volume 0.16M
Average 0.16M
ORMP Total Current Liabilities
All obligations due within one year.
Oramed Pharmaceuticals Inc.NASDAQ: ORMP
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 92.3% from a year ago
Total current liabilities stood at $10.56M at the end of Q1 FY2026, up 92.3% from a year earlier and down 44.7% from the prior quarter. Over 3 fiscal years it compounded at +49.2% a year.
Context
- Total current liabilities amounted to 3.9% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +92.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 19.09M USD
- Year-over-year change
- +235.7%
- 4-year CAGR
- +30.0%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.09M | +235.7% |
| FY2024 | 2024-12-31 | 5.69M | -89.3% |
| FY2023 | 2023-12-31 | 53.21M | +826.1% |
| FY2022 | 2022-12-31 | 5.75M | -14.0% |
| FY2021 | 2021-08-31 | 6.68M | — |
Total Current Liabilities vs competitors
How ORMP compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +92.3% is the 2nd highest of 11, against a peer median of -2.6%.
- Total current liabilities amounts to 3.9% of total assets for ORMP, versus a peer median of 9.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $95.94M USD | +73.0% | -3.9% | 44.0% | |
| Mar 2026 | $15.75M USD | +69.2% | +5.8% | 7.0% | |
| Dec 2025 | $13.61M USD | +60.9% | -4.5% | 24.3% | |
| Mar 2026 | €11.4M EUR | -29.6% | -0.1% | 23.3% | |
| Mar 2026 | $10.56M USD | +92.3% | +49.2% | 3.9% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $8.08M USD | +13.1% | +19.5% | 7.4% |
| Mar 2026 | $6.73M USD | -37.5% | -8.0% | 31.1% | |
IMAImageneBio Inc | Mar 2026 | $6.63M USD | -24.6% | -19.5% | 4.9% |
| Mar 2026 | $6.53M USD | +243.9% | +35.7% | 11.1% | |
| Mar 2026 | $4.25M USD | -41.9% | -34.4% | 4.2% | |
| Mar 2026 | $3.55M USD | -18.3% | +15.4% | 6.7% | |
| Peer median (excluding ORMP) | — | -2.6% | -2.0% | 9.2% | |
Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Aug 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77.25M | 40.46M | 9.06M | 54.42M | 45.95M |
| Short-term Investments | 16.9M | 115.26M | 152.99M | 87.51M | 79.95M |
| Net Receivables | 0 | 0 | 0 | 0 | 4.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.2M | 1.39M | 537K | 1.29M | 2.74M |
| Total Current Assets | 95.34M | 157.11M | 162.58M | 143.22M | 133.27M |
| Property, Plant & Equipment (Net) | 932K | 1.81M | 1.57M | 1.11M | 1.34M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 6.69M | 2.7M | 56.37M | 10.91M | 93.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 25.04M | 24K | 34K | 34K | 2.52M |
| Total Non-current Assets | 32.66M | 4.53M | 57.97M | 12.06M | 97.59M |
| Total Assets | 128M | 161.64M | 220.55M | 155.28M | 230.86M |
| Account Payables | 2.61M | 2.18M | 551K | 789K | 443K |
| Short-term Debt | 130K | 247K | 51.01M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 3.2M | 0 |
| Deferred Revenue | 2.7M | 1.34M | 0 | 0 | 1.35M |
| Other Current Liabilities | (1.37M) | (191K) | 325K | 1.07M | 2.37M |
| Total Current Liabilities | 6.68M | 5.75M | 53.21M | 5.69M | 19.09M |
| Long-term Debt | 403K | 647K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 11K | 11K | 0 | 0 | 7.91M |
| Deferred Revenue (Non-current) | 4.24M | 4M | 4M | 4M | 3.27M |
| Other Non-current Liabilities | 145K | 82K | 102K | 90K | 314K |
| Total Non-current Liabilities | 4.8M | 4.74M | 4.44M | 4.25M | 12.03M |
| Total Liabilities | 11.48M | 10.49M | 57.66M | 9.93M | 31.12M |
| Common Stock | 424K | 476K | 485K | 480K | 472K |
| Retained Earnings | (114.85M) | (163.08M) | (157.56M) | (176.62M) | (123.44M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 230.2M | 314.42M | 0 | 0 | 0 |
| Minority Interest | 744K | (656K) | (928K) | (918K) | 0 |
| Total Equity | 116.52M | 151.16M | 162.89M | 145.35M | 199.74M |
| Total Debt | 533K | 894K | 51.62M | 372K | 825K |
| Net Debt | (76.71M) | (39.57M) | 42.57M | (54.05M) | (45.12M) |
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
Intrinsic Alpha fair value
Locked
Current Price
$3.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.